HUIZHOU, China, May 9, 2025 /PRNewswire/ -- Desay Battery, a global leading energy storage solution provider, showcased its innovations at The Smarter E Europe 2025 exhibition in Germany, Europe's largest energy industry exhibition alliance, which took place from May 7 to 9 in Munich.
During the event, Desay Battery launched its new UPS 2.0 battery. This innovative solution is tailored for data center operators, IT departments of large enterprises, network and communications service providers, and more. Compatibility with existing systems and adherence to stringent safety and environmental protection standards highlight its versatility. The UPS 2.0 features a single lithium-ion cabinet that supports 300kVA and is designed for a lifespan of up to 15 years, effectively reducing project costs. Additionally, the intelligent monitoring system enables real-time tracking of battery status and predictive maintenance, while active safety management is enhanced through optional early fire detection and access to a cloud-based security network management platform.
Following the UPS 2.0 launch, Desay Battery signed a strategic agreement with TÜV Rheinland to accelerate European market expansion, covering EU certification for UPS 2.0 (49kWh, 8C) and its 5MWh energy storage container. The company also established a 2GW partnership framework with DOS Primärenergie Sonne GmbH (DOS), enhancing renewable energy collaboration across Middle Eastern and Latin American markets. These collaborations strengthen Desay's global energy storage supply chain position while creating a replicable model for Gulf countries' energy transition. The strategic moves underscore Desay's commitment to international market development and sustainable energy solutions through technological innovation and cross-border partnerships.
Moreover, Desay Battery features a range of standout products at smarter E Europe 2025, including high-performance lithium-ion cells (DLP-100, DLP-280, DLP-314), the DSP-60 sodium-ion battery, and modular energy storage systems with 100Ah and 280Ah lithium modules. More highlights are the Lumos 215kWh and 344kWh C38I DC ESS energy storage cabinets, 10-25kWh LV Residential ESS, 21kWh HV DCDC Residential ESS (280Ah), and the Vita 5MWh Utility ESS liquid-cooled container storage system along with UPS battery cabinets.
Recently, Desay Battery was included in the BloombergNEF Energy Storage Tier 1 List for Q2 2025. Looking ahead, Desay Battery plans to further expand its presence in the global energy storage market and continue to invest in R&D to meet the growing demand for clean energy.
For more information, please visit http://www.desayest.com.
Photo - https://mma.prnasia.com/media2/2679032/the_smarter_E_Europe.jpg?p=medium600
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Desay Battery brings innovative energy storage solutions to the smarter E Europe 2025, signs key cooperation agreements with TÜV Rheinland and DOS
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.
"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."
Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.
To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.
Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.
"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
